https://www.selleckchem.com/pr....oducts/abemaciclib.h
AEs were generally higher in those with HF than without HF; however, compared with placebo, empagliflozin did not increase risk of developing AEs over the first year of treatment. In the EMPA-REG OUTCOME trial, the use of empagliflozin led to early and beneficial effects on clinical, metabolic, and HF outcomes in patients with type 2 diabetes with or without HF at baseline, which were already apparent within 12weeks from initiation of treatment. Over the first year of treatment, no safety concern was detected with the use of empagli
Like
Comment
Share
